ClinicalTrials.gg
CompletedNCT02092467Updated Aug 17, 2021Results posted

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis

A Phase 4 interventional study of tofacitinib and tofacitinib in Arthritis, Rheumatoid, sponsored by Pfizer. Completed at 345 sites in 30 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-08-17.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,372
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.

Enrollment
2nd of 43
4,372 · median 170
Started
2014
with 2 others
Phase 4
12 of 43
4 open now
Registered
22nd of 43
by date
Lead sponsor
25 of 43
Pfizer

Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 4, and was the 22nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tofacitinib

tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tofacitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

03

Conditions studied

  • Arthritis, Rheumatoid

Keywords

  • Post-marketing
  • Phase 4
  • Open-label
  • Safety Surveillance
  • CP690550
  • Xeljanz
  • oral treatment
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe rheumatoid arthritis
  • Taking methotrexate without adequate control of symptoms
  • Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)

Exclusion criteria

Exclusion Criteria:

  • Current or recent infection
  • laboratory abnormalities
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,372 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1

    Drug: tofacitinib

  • Experimental
    Treatment Arm 2

    Drug: tofacitinib

  • Active comparator
    Treatment Arm 3

    TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.

    Biological: adalimumab · Biological: etanercept

Interventions

  • Oral tablet, 5 mg BID

  • Oral tablet, 10 mg BID

  • Biologicaladalimumab

    Pre-filled syringe, 40 mg subcutaneous injection, every other week

    Also known as: Humira

  • Biologicaletanercept

    Pre-filled syringe, 50 mg subcutaneous injection, every week

    Also known as: Enbrel

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)

    Incidence rate (number of participants with event per 100 participant year \[PY\]) was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Malignancy events, excluding NMSC were adjudicated by a steering committee. The risk period (RP) was the last contact date. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  2. Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)

    MACE included the cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke of any classification, including reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

Secondary outcomes

  1. Incidence Rate of Non-fatal Stroke

    Non-fatal stroke included reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  2. Incidence Rate of Non-fatal Myocardial Infarction

    Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  3. Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis

    Opportunistic infections (OI) were reviewed and adjudicated by the opportunistic infection review committee (OIRC). Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  4. Incidence Rate of Adjudicated Hepatic Events

    Hepatic events (adjudicated) included drug-induced liver injury (DILI) - probable, highly likely and definite, DILI - listed separately, DILI - cases meeting classification and severity, participants with elevations of transaminase levels greater than (\>) 1\* upper limit of normal (ULN), greater than or equal to (\>=) 3\*ULN, \>=5\*ULN (based on laboratory values). Incidence rate was the total number of participants with admissible events divided by total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was minimum of The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  5. Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)

    Cardiovascular events (adjudicated) were death (coronary and non-coronary), MI, all coronary revascularization, unstable angina, new ischemic heart disease, stroke (fatal and non-fatal), transient ischemic attack (TIA), congestive heart failure (CHF), peripheral arterial vascular disease (PAVD), deep vein thrombosis, pulmonary embolism, arterial embolism, arterial thrombosis. Incidence rate was total number of participants with admissible events divided by total (for all qualifying participants) time at risk for cohort/treatment group of interest. Risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  6. Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE was any untoward medical occurrence post treatment; event need not necessarily had causal relationship with treatment or usage. SAE: any untoward medical occurrence at any dose: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly. TEAE: event that occurred for first time during effective duration of treatment and not seen prior to start of treatment or event seen prior to start of treatment but increase in severity during treatment. Risk period (RP) for AE: minimum of last contact date or last study treatment dose date+28 days. RP for SAEs: last contact date. Last contact date was maximum: AE start, AE stop, last study visit, withdrawal and telephone contact. In case of death, last contact was death date. First events counted within RP. Participant did not have event or had event outside risk period were censored at end of RP.

    Time frame: AEs: Baseline up to minimum of last contact date or last study treatment dose date+28 days (maximum up to 72 months); SAEs: Baseline up to minimum of last contact date (maximum up to 72 months)

  7. Number of Participants With Clinically Significant Abnormal Laboratory Parameters

    Clinically significant laboratory abnormalities: Hematology: hemoglobin, hematocrit, erythrocytes with primary criteria as less than \[\<\] 0.8\* lower limit of normal \[LLN\]), platelets (\<0.5\* LLN; \>1.75\* ULN), leukocytes (\<0.6\*LLN; \>1.5\*ULN), lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes (\<0.8\*LLN; \>1.2\*ULN), eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes (\>1.2\*ULN); urinalysis: urine glucose, urine protein, urine hemoglobin, and leukocyte esterase (\>=1); chemistry: bilirubin, indirect bilirubin (\>1.5\*ULN) aspartate aminotransferase, alanine aminotransferase (\>3.0\*ULN), creatinine, triglycerides, cholesterol (\>1.3\*ULN) and HDL cholesterol (\<0.8\*LLN). Risk period (RP) was minimum of last contact date or last study treatment dose date+28 days. Last contact date was (date of death or maximum of dates: AE start, AE stop, last study visit, withdrawal, telephone contact). Participants without event or event outside RP were censored at end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  8. Incidence Rate of Adjudicated All-Cause Deaths

    All-cause death was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths (adjudicated by Adjudication Committee) was reported in this outcome measure. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  9. Number of Participants With Reasons For Permanent or Temporary Discontinuation of Study Medication

    Number of participants who permanent or temporary discontinued study medication due to any AE, treatment related AEs, Coronavirus disease 2019 (COVID 19) related AEs, and herpes zoster were reported. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

    Time frame: Baseline up to last contact date (maximum up to 72 months)

  10. Change From Baseline in Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (milligrams per liter \[mg/L\]) and patient's global assessment of disease activity (PtGA) on a 100 mm Visual Analog Scale (VAS) (scores ranging from 0 millimeter \[mm\] \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root.

    Time frame: Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

  11. Change From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and physician's global assessment of health (PhyGA) both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

    Time frame: Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

  12. Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

    Time frame: Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

  13. Percentage of Participants Who Achieved Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria

    ACR-EULAR Boolean-based definition of remission participant must satisfy all of the following: TJC28 \<=1, SJC28 \<=1, CRP \<=10 mg/L, PtGA on a 0-100 mm scale, higher scores indicate greater affection due to disease activity.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  14. Percentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  15. Percentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  16. Percentage of Participants With Simplified Disease Activity Index (SDAI) <=11

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  17. Percentage of Participants With Clinical Disease Activity Index (CDAI) <=10

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  18. Percentage of Participants With Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) <=3.2

    DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  19. Number of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response

    ACR20 response is a \>= 20% improvement in TJC (28) and SJC (28) and \>=20% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  20. Number of Participants With an American College of Rheumatology 50% (ACR50) Response

    ACR50 response is a \>= 50% improvement in TJC (28) and SJC (28) and \>=50% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  21. Number of Participants With an American College of Rheumatology 70% (ACR70) Response

    ACR70 response is a \>= 70% improvement in TJC (28) and SJC (28) and \>=70% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

    Time frame: Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72

  22. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

    HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

    Time frame: Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

07

Results

Posted Aug 17, 2021

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Started145714571458
Treated145514561451
Completed10539981060
Not completed404459398
Withdrew: Death496638
Withdrew: Lost to follow-up383540
Withdrew: Global deterioration of health status100
Withdrew: Other323024
Withdrew: Withdrawal by subject282327289
Withdrew: Randomized but not treated217

Outcome measures

PrimaryIncidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)

Incidence rate (number of participants with event per 100 participant year \[PY\]) was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Malignancy events, excluding NMSC were adjudicated by a steering committee. The risk period (RP) was the last contact date. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDAll TofacitinibTNFi
Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC)1.13 (0.87 to 1.45)1.13 (0.86 to 1.45)1.13 (0.94 to 1.35)0.77 (0.55 to 1.04)
Statistical analysis
  • All Tofacitinib vs TNFi · Hazard ratio (hr): 1.48 · 95% CI 1.04 to 2.09Primary comparison. Non-inferiority was to be claimed between All Tofacitinib and TNFi if the upper limit of the 95% CI for HR was \< 1.8 (non-inferiority criterion).
  • Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID · Hazard ratio (hr): 1.00 · 95% CI 0.70 to 1.43Secondary comparison. Non-inferiority was to be claimed between tofacitinib 10 mg BID and tofacitinib 5 mg BID if the upper limit of the 95% CI for HR was \< 2.0 (non-inferiority criterion).
  • Tofacitinib 5 mg BID vs TNFi · Hazard ratio (hr): 1.47 · 95% CI 1.00 to 2.18Supportive analysis to the primary comparison between All Tofacitinib vs TNFi.
  • Tofacitinib 10 mg BID vs TNFi · Hazard ratio (hr): 1.48 · 95% CI 1.00 to 2.19Supportive analysis to the primary comparison between All Tofacitinib vs TNFi.
PrimaryIncidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)

MACE included the cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke of any classification, including reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDAll TofacitinibTNFi
Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE)0.91 (0.67 to 1.21)1.05 (0.78 to 1.38)0.98 (0.79 to 1.19)0.73 (0.52 to 1.01)
Statistical analysis
  • All Tofacitinib vs TNFi · Hazard ratio (hr): 1.33 · 95% CI 0.91 to 1.94Primary comparison. Non-inferiority was to be claimed between All Tofacitinib and TNFi if the upper limit of the 95% CI for HR was \< 1.8 (non-inferiority criterion).
  • Tofacitinib 5 mg BID vs Tofacitinib 10 mg BID · Hazard ratio (hr): 1.15 · 95% CI 0.77 to 1.71Secondary Comparison. Non-inferiority was to be claimed between tofacitinib 10 mg BID and tofacitinib 5 mg BID if the upper limit of the 95% CI for HR was \<2.0 (non-inferiority criterion).
  • Tofacitinib 5 mg BID vs TNFi · Hazard ratio (hr): 1.24 · 95% CI 0.81 to 1.91Supportive analysis to the primary comparison between All Tofacitinib vs TNFi.
  • Tofacitinib 10 mg BID vs TNFi · Hazard ratio (hr): 1.43 · 95% CI 0.94 to 2.18Supportive analysis to the primary comparison between All Tofacitinib vs TNFi.
SecondaryIncidence Rate of Non-fatal Stroke

Non-fatal stroke included reversible focal neurologic defects with imaging evidence of a new cerebral lesion consistent with ischemia or hemorrhage. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Non-fatal Stroke
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Incidence Rate of Non-fatal Stroke0.27 (0.15 to 0.45)0.33 (0.19 to 0.53)0.34 (0.20 to 0.54)
SecondaryIncidence Rate of Non-fatal Myocardial Infarction

Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 60 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Non-fatal Myocardial Infarction
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Incidence Rate of Non-fatal Myocardial Infarction0.37 (0.22 to 0.57)0.33 (0.19 to 0.53)0.16 (0.07 to 0.31)
SecondaryIncidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis

Opportunistic infections (OI) were reviewed and adjudicated by the opportunistic infection review committee (OIRC). Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Incidence Rate of Adjudicated Opportunistic Infection Events Including Tuberculosis0.76 (0.54 to 1.04)0.91 (0.66 to 1.22)0.42 (0.26 to 0.64)
SecondaryIncidence Rate of Adjudicated Hepatic Events

Hepatic events (adjudicated) included drug-induced liver injury (DILI) - probable, highly likely and definite, DILI - listed separately, DILI - cases meeting classification and severity, participants with elevations of transaminase levels greater than (\>) 1\* upper limit of normal (ULN), greater than or equal to (\>=) 3\*ULN, \>=5\*ULN (based on laboratory values). Incidence rate was the total number of participants with admissible events divided by total (for all qualifying participants) time at risk for the cohort/treatment group of interest. The risk period (RP) was minimum of The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated Hepatic Events
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Incidence Rate of Adjudicated Hepatic Events0.90 (0.66 to 1.20)1.51 (1.18 to 1.91)0.70 (0.49 to 0.97)
SecondaryIncidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)

Cardiovascular events (adjudicated) were death (coronary and non-coronary), MI, all coronary revascularization, unstable angina, new ischemic heart disease, stroke (fatal and non-fatal), transient ischemic attack (TIA), congestive heart failure (CHF), peripheral arterial vascular disease (PAVD), deep vein thrombosis, pulmonary embolism, arterial embolism, arterial thrombosis. Incidence rate was total number of participants with admissible events divided by total (for all qualifying participants) time at risk for cohort/treatment group of interest. Risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. Last contact date was maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). In case of death, last contact date was death date. First events counted within RP. Participant did not have an event or had an event outside risk period were censored at end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Incidence Rate of Adjudicated Cardiovascular Events Other Than Major Adverse Cardiovascular Events (MACE)1.21 (0.92 to 1.55)1.45 (1.13 to 1.83)1.05 (0.78 to 1.38)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE was any untoward medical occurrence post treatment; event need not necessarily had causal relationship with treatment or usage. SAE: any untoward medical occurrence at any dose: resulted in death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly. TEAE: event that occurred for first time during effective duration of treatment and not seen prior to start of treatment or event seen prior to start of treatment but increase in severity during treatment. Risk period (RP) for AE: minimum of last contact date or last study treatment dose date+28 days. RP for SAEs: last contact date. Last contact date was maximum: AE start, AE stop, last study visit, withdrawal and telephone contact. In case of death, last contact was death date. First events counted within RP. Participant did not have event or had event outside risk period were censored at end of RP.

Time frame:
AEs: Baseline up to minimum of last contact date or last study treatment dose date+28 days (maximum up to 72 months); SAEs: Baseline up to minimum of last contact date (maximum up to 72 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
AEs133313441308
SAEs373420339
SecondaryNumber of Participants With Clinically Significant Abnormal Laboratory Parameters

Clinically significant laboratory abnormalities: Hematology: hemoglobin, hematocrit, erythrocytes with primary criteria as less than \[\<\] 0.8\* lower limit of normal \[LLN\]), platelets (\<0.5\* LLN; \>1.75\* ULN), leukocytes (\<0.6\*LLN; \>1.5\*ULN), lymphocytes, lymphocytes/leukocytes, neutrophils, neutrophils/leukocytes (\<0.8\*LLN; \>1.2\*ULN), eosinophils, eosinophils/leukocytes, monocytes, monocytes/leukocytes (\>1.2\*ULN); urinalysis: urine glucose, urine protein, urine hemoglobin, and leukocyte esterase (\>=1); chemistry: bilirubin, indirect bilirubin (\>1.5\*ULN) aspartate aminotransferase, alanine aminotransferase (\>3.0\*ULN), creatinine, triglycerides, cholesterol (\>1.3\*ULN) and HDL cholesterol (\<0.8\*LLN). Risk period (RP) was minimum of last contact date or last study treatment dose date+28 days. Last contact date was (date of death or maximum of dates: AE start, AE stop, last study visit, withdrawal, telephone contact). Participants without event or event outside RP were censored at end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Laboratory Parameters
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Number of Participants With Clinically Significant Abnormal Laboratory Parameters238252167
SecondaryIncidence Rate of Adjudicated All-Cause Deaths

All-cause death was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths (adjudicated by Adjudication Committee) was reported in this outcome measure. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Number · participants with event/100 PY
Incidence Rate of Adjudicated All-Cause Deaths
participants with event/100 PYTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Deaths-Total0.50 (0.33 to 0.74)0.80 (0.57 to 1.09)0.34 (0.20 to 0.54)
Deaths - Infections0.08 (0.02 to 0.20)0.18 (0.08 to 0.35)0.06 (0.01 to 0.17)
Deaths - Cardiovascular Events0.25 (0.13 to 0.43)0.41 (0.25 to 0.63)0.20 (0.10 to 0.36)
Deaths - Malignancies0.10 (0.03 to 0.23)0.00 (0.00 to 0.08)0.02 (0.00 to 0.11)
Deaths - Other Causes0.08 (0.02 to 0.20)0.21 (0.10 to 0.38)0.06 (0.01 to 0.17)
SecondaryNumber of Participants With Reasons For Permanent or Temporary Discontinuation of Study Medication

Number of participants who permanent or temporary discontinued study medication due to any AE, treatment related AEs, Coronavirus disease 2019 (COVID 19) related AEs, and herpes zoster were reported. The risk period (RP) was the minimum of last contact date or last study treatment dose date + 28 days. The last contact date was the maximum of (AE start date, AE stop date, last study visit date, withdrawal date, telephone contact date). If a participant died, last contact date was the death date. First events were counted within the RP. If a participant did not have an event or had an event but outside the risk period, the participant was censored at the end of RP.

Time frame:
Baseline up to last contact date (maximum up to 72 months)
Reported as:
Count of participants · Participants
Number of Participants With Reasons For Permanent or Temporary Discontinuation of Study Medication
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Permanent discontinuation: AE210304210
Temporary discontinuation: AEs665736576
Permanent discontinuation: treatment related AE111179114
Temporary discontinuation: treatment related AE407458297
Permanent discontinuation: COVID-19 Related AEs010
Temporary discontinuation: COVID-19 Related AEs011
Permanent discontinuation: Herpes Zoster6132
Temporary discontinuation: Herpes Zoster10411033
SecondaryChange From Baseline in Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (milligrams per liter \[mg/L\]) and patient's global assessment of disease activity (PtGA) on a 100 mm Visual Analog Scale (VAS) (scores ranging from 0 millimeter \[mm\] \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96; ln = natural logarithm, sqrt = square root.

Time frame:
Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Change at Month 2-2.00 ± 0.03-2.14 ± 0.03-1.89 ± 0.03
Change at Month 3-2.28 ± 0.03-2.42 ± 0.03-2.19 ± 0.03
Change at Month 6-2.50 ± 0.03-2.68 ± 0.03-2.40 ± 0.03
Change at Month 9-2.64 ± 0.03-2.80 ± 0.03-2.54 ± 0.03
Change at Month 12-2.70 ± 0.03-2.85 ± 0.03-2.60 ± 0.03
Change at Month 15-2.78 ± 0.03-2.93 ± 0.03-2.67 ± 0.03
Change at Month 18-2.78 ± 0.03-2.95 ± 0.03-2.76 ± 0.03
Change at Month 21-2.82 ± 0.03-2.97 ± 0.03-2.76 ± 0.03
Change at Month 24-2.82 ± 0.03-2.99 ± 0.03-2.77 ± 0.03
Change at Month 27-2.91 ± 0.03-3.03 ± 0.03-2.81 ± 0.03
Change at Month 30-2.92 ± 0.03-3.03 ± 0.03-2.89 ± 0.03
Change at Month 33-2.89 ± 0.03-3.03 ± 0.03-2.89 ± 0.03
Change at Month 36-2.91 ± 0.03-2.98 ± 0.03-2.88 ± 0.03
Change at Month 39-2.96 ± 0.03-2.97 ± 0.03-2.91 ± 0.03
Change at Month 42-2.95 ± 0.03-3.05 ± 0.03-2.93 ± 0.03
Change at Month 45-2.94 ± 0.04-2.96 ± 0.04-2.97 ± 0.04
Change at Month 48-2.98 ± 0.04-2.99 ± 0.04-2.93 ± 0.04
Change at Month 51-3.00 ± 0.04-2.95 ± 0.04-2.96 ± 0.04
Change at Month 54-2.99 ± 0.04-3.01 ± 0.05-2.99 ± 0.05
Change at Month 57-2.97 ± 0.05-2.93 ± 0.05-3.02 ± 0.05
Change at Month 60-3.09 ± 0.06-2.94 ± 0.06-3.01 ± 0.06
Change at Month 63-3.07 ± 0.08-2.99 ± 0.07-3.05 ± 0.08
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and physician's global assessment of health (PhyGA) both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

Time frame:
Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Reported as:
Least squares mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Change at Month 2-22.95 ± 0.33-23.84 ± 0.33-22.24 ± 0.33
Change at Month 3-25.73 ± 0.30-26.81 ± 0.30-25.26 ± 0.30
Change at Month 6-27.63 ± 0.28-28.93 ± 0.28-27.21 ± 0.28
Change at Month 9-28.81 ± 0.28-30.07 ± 0.28-28.29 ± 0.28
Change at Month 12-29.56 ± 0.27-30.46 ± 0.27-28.71 ± 0.27
Change at Month 15-30.20 ± 0.25-31.15 ± 0.26-29.30 ± 0.26
Change at Month 18-30.14 ± 0.26-31.29 ± 0.26-30.18 ± 0.26
Change at Month 21-30.42 ± 0.26-31.46 ± 0.26-30.36 ± 0.26
Change at Month 24-30.51 ± 0.26-31.56 ± 0.26-30.33 ± 0.26
Change at month 27-31.16 ± 0.25-31.85 ± 0.26-30.53 ± 0.26
Change at Month 30-31.27 ± 0.25-32.02 ± 0.25-31.24 ± 0.25
Change at Month 33-31.06 ± 0.26-31.91 ± 0.26-31.20 ± 0.26
Change at Month 36-31.26 ± 0.26-31.52 ± 0.27-31.09 ± 0.26
Change at Month 39-31.77 ± 0.25-31.51 ± 0.26-31.36 ± 0.26
Change at Month 42-31.62 ± 0.27-32.09 ± 0.28-31.24 ± 0.27
Change at Month 45-31.27 ± 0.29-31.67 ± 0.30-31.85 ± 0.30
Change at Month 48-31.87 ± 0.31-31.59 ± 0.32-31.68 ± 0.32
Change at Month 51-32.15 ± 0.33-31.52 ± 0.34-31.72 ± 0.34
Change at Month 54-31.91 ± 0.33-32.33 ± 0.35-31.95 ± 0.35
Change at Month 57-31.58 ± 0.41-31.61 ± 0.42-31.98 ± 0.42
Change at Month 60-32.84 ± 0.46-31.57 ± 0.46-32.23 ± 0.48
Change at Month 63-32.27 ± 0.63-32.12 ± 0.62-32.27 ± 0.66
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

Time frame:
Baseline, Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) Score at Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Change at Month 2-21.99 ± 0.32-22.84 ± 0.32-21.30 ± 0.32
Change at Month 3-24.76 ± 0.29-25.77 ± 0.29-24.29 ± 0.30
Change at Month 6-26.59 ± 0.27-27.82 ± 0.28-26.21 ± 0.28
Change at Month 9-27.78 ± 0.27-29.03 ± 0.27-27.30 ± 0.27
Change at Month 12-28.52 ± 0.26-29.38 ± 0.26-27.73 ± 0.26
Change at Month 15-29.17 ± 0.25-30.06 ± 0.25-28.38 ± 0.25
Change at Month 18-29.12 ± 0.25-30.21 ± 0.26-29.15 ± 0.25
Change at Month 21-29.45 ± 0.25-30.49 ± 0.26-29.40 ± 0.25
Change at Month 24-29.54 ± 0.25-30.49 ± 0.26-29.39 ± 0.25
Change at Month 27-30.16 ± 0.24-30.82 ± 0.25-29.54 ± 0.25
Change at Month 30-30.27 ± 0.24-30.99 ± 0.25-30.24 ± 0.25
Change at Month 33-30.05 ± 0.25-30.85 ± 0.25-30.23 ± 0.25
Change at Month 36-30.29 ± 0.25-30.50 ± 0.26-30.14 ± 0.25
Change at Month 39-30.78 ± 0.24-30.49 ± 0.25-30.35 ± 0.25
Change at Month 42-30.66 ± 0.26-31.05 ± 0.27-30.25 ± 0.26
Change at Month 45-30.28 ± 0.28-30.68 ± 0.29-30.83 ± 0.29
Change at Month 48-30.85 ± 0.30-30.57 ± 0.32-30.69 ± 0.31
Change at Month 51-31.09 ± 0.32-30.50 ± 0.33-30.74 ± 0.33
Change at Month 54-31.03 ± 0.32-31.38 ± 0.33-31.02 ± 0.33
Change at Month 57-30.62 ± 0.40-30.75 ± 0.41-30.95 ± 0.41
Change at Month 60-31.74 ± 0.45-30.57 ± 0.45-31.31 ± 0.47
Change at Month 63-31.23 ± 0.58-31.08 ± 0.57-31.65 ± 0.60
SecondaryPercentage of Participants Who Achieved Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria

ACR-EULAR Boolean-based definition of remission participant must satisfy all of the following: TJC28 \<=1, SJC28 \<=1, CRP \<=10 mg/L, PtGA on a 0-100 mm scale, higher scores indicate greater affection due to disease activity.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 23.834.993.22
Month 35.737.726.10
Month 69.1010.667.80
Month 910.8512.608.96
Month 1211.2213.069.12
Month 1512.5615.1810.28
Month 1812.1016.0411.78
Month 2112.9015.2213.45
Month 2413.6015.9913.35
Month 2713.2417.5914.82
Month 3013.4616.9614.31
Month 3313.8815.9714.82
Month 3614.5116.1814.53
Month 3913.7814.3015.15
Month 4214.7915.4115.01
Month 4514.8915.4615.74
Month 4815.1413.9017.28
Month 5114.3315.5016.26
Month 5414.0116.4216.36
Month 5715.5414.1615.08
Month 6011.3112.7315.58
Month 6311.7616.9615.25
Month 669.0216.7913.11
Month 6913.0419.5714.58
Month 728.3322.2213.33
SecondaryPercentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) Less Than or Equal to (<=) 3.3
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 24.627.034.15
Month 39.1911.147.84
Month 612.3814.2310.40
Month 915.9017.7212.75
Month 1215.8918.6913.92
Month 1518.2620.2915.90
Month 1818.6821.9616.79
Month 2120.8922.0717.93
Month 2420.4422.7618.93
Month 2721.9123.6221.12
Month 3021.3123.6821.91
Month 3321.4325.0622.19
Month 3622.4724.3521.80
Month 3922.9924.2121.48
Month 4224.5924.2323.41
Month 4525.2723.2023.26
Month 4825.3223.2024.20
Month 5123.3523.8524.24
Month 5422.3424.0924.55
Month 5724.1023.8224.83
Month 6018.6520.3025.23
Month 6319.0023.4823.32
Month 6614.7521.3720.49
Month 6917.3917.3922.92
Month 7216.6722.2213.33
SecondaryPercentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=2.8
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 24.707.404.36
Month 39.2611.067.76
Month 612.8714.3110.32
Month 915.7618.0913.25
Month 1216.3318.6214.64
Month 1518.0321.3616.41
Month 1819.8222.1217.93
Month 2121.3522.5518.70
Month 2420.4422.7619.48
Month 2722.7723.2921.51
Month 3021.8824.1822.31
Month 3322.2425.9122.36
Month 3623.2225.3021.64
Month 3923.9224.3021.90
Month 4225.0224.9523.66
Month 4525.9524.2323.85
Month 4825.5524.4424.31
Month 5124.5024.8925.11
Month 5423.2325.0025.45
Month 5724.3224.0425.75
Month 6019.8820.9126.48
Month 6320.8122.1722.87
Month 6613.9322.1417.21
Month 6919.5719.5718.75
Month 7216.6722.2213.33
SecondaryPercentage of Participants With Simplified Disease Activity Index (SDAI) <=11

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/L). SDAI total score ranges from 0 to 86 with higher score indicating greater disease activity. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity. SDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10 + CRP/10.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) <=11
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 230.7635.0228.08
Month 341.4745.0037.99
Month 650.8553.5645.80
Month 956.4059.8252.90
Month 1257.8761.1154.93
Month 1561.1263.9257.39
Month 1862.1065.1960.41
Month 2162.7565.2661.21
Month 2463.1766.1561.59
Month 2765.1766.9763.67
Month 3067.2368.3565.64
Month 3365.7568.8265.36
Month 3667.3366.6165.48
Month 3969.7467.1166.03
Month 4268.9670.7266.41
Month 4568.3668.9767.55
Month 4867.2864.7667.94
Month 5167.9167.5167.78
Month 5464.8968.6168.00
Month 5763.5166.2968.21
Month 6063.3066.6764.17
Month 6361.5468.2664.57
Month 6659.0271.7659.02
Month 6960.8765.2268.75
Month 7250.0066.6760.00
SecondaryPercentage of Participants With Clinical Disease Activity Index (CDAI) <=10

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PhyGA both assessed on a 0 to 100 mm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76 with higher score indicating greater disease activity. CDAI \<=2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity. CDAI = (28TJC) + (28SJC) + PhyGA/10 + PtGA/10.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Disease Activity Index (CDAI) <=10
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 229.4734.2526.92
Month 340.0743.9035.99
Month 649.3651.8343.63
Month 955.4058.7850.91
Month 1256.5659.3853.57
Month 1560.3162.7055.93
Month 1860.5164.0259.42
Month 2161.3764.9460.20
Month 2462.7865.2561.19
Month 2764.9366.3962.87
Month 3067.1567.8465.00
Month 3365.5067.7165.03
Month 3666.6765.1564.66
Month 3968.6466.4065.61
Month 4268.4469.1065.82
Month 4567.9768.6667.16
Month 4866.7163.1567.58
Month 5167.7765.8767.63
Month 5464.5467.8868.00
Month 5762.6165.3967.98
Month 6063.0065.1565.42
Month 6362.9066.5266.37
Month 6657.3867.9461.48
Month 6958.7065.2266.67
Month 7250.0066.6753.33
SecondaryPercentage of Participants With Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) <=3.2

DAS28 is a measure of disease activity in participants with rheumatoid arthritis based on a 28-joint assessment. DAS28-4 (CRP) was calculated from number of painful joints out of 28 joints (TJC28) and number of swollen joints out of 28 joints (SJC28), CRP (mg/L) and PtGA on a 100 mm VAS (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[worst\], higher scores indicated worse health condition). Total DAS28-4 (CRP) score range: 0 to 9.4, higher score indicated more disease activity. DAS28-4 (CRP) \<= 3.2 indicates low disease activity and \> 3.2 to \<=5.1 indicates moderate disease activity, \>5.1 indicates high disease activity, and DAS28-4 (CRP) \< 2.6 indicates remission. DAS28-4 (CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP in mg/L +1) + 0.014\*PtGA in mm+ 0.96.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Activity Score 28-4 (DAS28-4) C-reactive Protein (CRP) <=3.2
percentage of participantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 231.5535.5728.36
Month 341.6846.0537.54
Month 650.2854.8744.88
Month 956.1159.0150.91
Month 1257.7360.0653.05
Month 1560.3863.5455.03
Month 1861.7263.8658.51
Month 2162.2963.6759.27
Month 2461.9364.1159.78
Month 2764.2267.6360.56
Month 3064.6665.4963.22
Month 3363.8066.0262.82
Month 3664.4364.6362.59
Month 3965.8565.1863.53
Month 4265.4367.9365.31
Month 4564.7465.7764.52
Month 4864.3964.5264.36
Month 5165.1966.4765.46
Month 5464.1866.2466.55
Month 5763.0663.6067.29
Month 6062.6964.2465.11
Month 6360.1864.3568.61
Month 6655.7466.4160.66
Month 6958.7056.5270.83
Month 7250.0061.1173.33
SecondaryNumber of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response

ACR20 response is a \>= 20% improvement in TJC (28) and SJC (28) and \>=20% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Count of participants · Participants
Number of Participants With an American College of Rheumatology 20 Percent (%) (ACR20) Response
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 2832867812
Month 3979992923
Month 69991012981
Month 910191004987
Month 121033992966
Month 1510171003969
Month 18981974937
Month 21955953949
Month 24956922922
Month 27961917913
Month 30932899931
Month 33935888922
Month 36907881887
Month 39896843887
Month 42905848883
Month 45780718790
Month 48654587639
Month 51535485518
Month 54434396400
Month 57337321302
Month 60243237232
Month 63163166161
Month 668510189
Month 69263637
Month 7251510
SecondaryNumber of Participants With an American College of Rheumatology 50% (ACR50) Response

ACR50 response is a \>= 50% improvement in TJC (28) and SJC (28) and \>=50% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Count of participants · Participants
Number of Participants With an American College of Rheumatology 50% (ACR50) Response
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 2402452336
Month 3528561460
Month 6605614533
Month 9620651577
Month 12631654577
Month 15652668582
Month 18633643609
Month 21607623608
Month 24622616592
Month 27620602596
Month 30599609610
Month 33585611594
Month 36603566592
Month 39595588561
Month 42592578587
Month 45521481519
Month 48422385424
Month 51350320346
Month 54284271268
Month 57200210209
Month 60152151150
Month 63100104103
Month 66526855
Month 69162027
Month 72367
SecondaryNumber of Participants With an American College of Rheumatology 70% (ACR70) Response

ACR70 response is a \>= 70% improvement in TJC (28) and SJC (28) and \>=70% improvement in 3 of the 5 remaining ACR-core criteria: 1) PGA of arthritis, 2) PtGA of arthritis, 3) participant's assessment of arthritis pain, 4) participant's assessment of functional disability by HAQ-DI, and 5) CRP (mg/L) at each visit. PGA: physician's global assessment of arthritis on VAS, 0 (very well) to 100 mm (worst arthritis), higher scores=worse condition. PtGA: participant's global assessment of arthritis on VAS, 0 mm (very well) to 100 mm (worst arthritis condition), higher scores = worse condition. Participant's assessment of arthritis pain: assessed on VAS, 0 mm (no pain) to 100 mm (most severe pain), higher score = more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (unable to do), higher score=more disability.

Time frame:
Month 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69 and 72
Reported as:
Count of participants · Participants
Number of Participants With an American College of Rheumatology 70% (ACR70) Response
ParticipantsTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Month 2152193113
Month 3253268199
Month 6282331234
Month 9328367291
Month 12337373284
Month 15359390304
Month 18358382325
Month 21362370322
Month 24349386328
Month 27374390342
Month 30369397358
Month 33357392355
Month 36362343351
Month 39371361338
Month 42376342343
Month 45313298298
Month 48256228238
Month 51216195199
Month 54159163160
Month 57128127118
Month 60798392
Month 63585764
Month 66253835
Month 6981514
Month 72254
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63

HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 domains of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. There were total of 30 items distributed in these 8 domains. Each item was scored on a 4-point scale from 0 to 3: 0= no difficulty; 1= some difficulty; 2= much difficulty; 3= unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.

Time frame:
Baseline, Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Months 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60 and 63
units on a scaleTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Change at Month 2-0.42 ± 0.02-0.45 ± 0.02-0.38 ± 0.02
Change at Month 3-0.45 ± 0.02-0.48 ± 0.02-0.42 ± 0.02
Change at Month 6-0.50 ± 0.02-0.51 ± 0.02-0.46 ± 0.02
Change at Month 9-0.51 ± 0.02-0.55 ± 0.02-0.47 ± 0.02
Change at Month 12-0.52 ± 0.02-0.53 ± 0.02-0.49 ± 0.02
Change at Month 15-0.53 ± 0.02-0.56 ± 0.02-0.51 ± 0.02
Change at Month 18-0.52 ± 0.02-0.56 ± 0.02-0.49 ± 0.02
Change at Month 21-0.53 ± 0.02-0.55 ± 0.02-0.50 ± 0.02
Change at Month 24-0.52 ± 0.02-0.57 ± 0.02-0.49 ± 0.02
Change at Month 27-0.52 ± 0.02-0.56 ± 0.02-0.51 ± 0.02
Change at Month 30-0.53 ± 0.02-0.55 ± 0.02-0.50 ± 0.02
Change at Month 33-0.51 ± 0.02-0.56 ± 0.02-0.52 ± 0.02
Change at Month 36-0.50 ± 0.02-0.54 ± 0.02-0.48 ± 0.02
Change at Month 39-0.51 ± 0.02-0.54 ± 0.02-0.49 ± 0.02
Change at Month 42-0.51 ± 0.02-0.52 ± 0.02-0.50 ± 0.02
Change at Month 45-0.50 ± 0.02-0.51 ± 0.02-0.51 ± 0.02
Change at Month 48-0.50 ± 0.02-0.50 ± 0.02-0.48 ± 0.02
Change at Month 51-0.53 ± 0.02-0.49 ± 0.02-0.50 ± 0.02
Change at Month 54-0.53 ± 0.02-0.51 ± 0.02-0.48 ± 0.02
Change at Month 57-0.49 ± 0.02-0.48 ± 0.02-0.48 ± 0.02
Change at Month 60-0.52 ± 0.03-0.49 ± 0.03-0.48 ± 0.03
Change at Month 63-0.54 ± 0.03-0.48 ± 0.03-0.48 ± 0.04

Adverse events

Collected over Baseline up to last contact date (maximum up to 72 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID49/1,455 (3.4%)373/1,455 (25.6%)1,108/1,455 (76.2%)
Tofacitinib 10 mg BID66/1,456 (4.5%)420/1,456 (28.8%)1,127/1,456 (77.4%)
TNFi38/1,451 (2.6%)339/1,451 (23.4%)1,056/1,451 (72.8%)
Most frequent serious events
Showing 10 of 674
Most frequent serious events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
PneumoniaInfections and infestations50/145556/145643/1451
OsteoarthritisMusculoskeletal and connective tissue disorders29/145523/145616/1451
Pulmonary embolismRespiratory, thoracic and mediastinal disorders10/145522/14561/1451
CellulitisInfections and infestations12/145513/145615/1451
Urinary tract infectionInfections and infestations14/145514/14569/1451
Rheumatoid arthritisMusculoskeletal and connective tissue disorders11/145510/145612/1451
Femur fractureInjury, poisoning and procedural complications10/14555/145611/1451
Herpes zosterInfections and infestations9/145511/14562/1451
BronchitisInfections and infestations10/14559/14567/1451
AnaemiaBlood and lymphatic system disorders9/14554/14561/1451
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFi
Upper respiratory tract infectionInfections and infestations319/1455318/1456264/1451
BronchitisInfections and infestations221/1455243/1456168/1451
Urinary tract infectionInfections and infestations190/1455220/1456186/1451
Rheumatoid arthritisMusculoskeletal and connective tissue disorders183/1455188/1456202/1451
FallInjury, poisoning and procedural complications177/1455160/1456159/1451
Herpes zosterInfections and infestations175/1455160/145659/1451
NasopharyngitisInfections and infestations168/1455172/1456164/1451
HypertensionVascular disorders129/1455152/1456127/1451
LymphopeniaBlood and lymphatic system disorders107/1455151/145636/1451
ArthralgiaMusculoskeletal and connective tissue disorders111/145590/1456124/1451

Baseline characteristics

Safety Analysis Set (SAS) included all participants who were randomized in the study and received at least one dose of the randomized investigational drug (tofacitinib or TNFi).

Age, Continuous
Age, Continuous(years)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFiTotal
Mean60.75 ± 6.8061.40 ± 7.0761.30 ± 7.4761.15 ± 7.12
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFiTotal
Female1169112411173410
Male286332334952
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFiTotal
Hispanic or Latino4384824701390
Not Hispanic or Latino10179749812972
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tofacitinib 5 mg BIDTofacitinib 10 mg BIDTNFiTotal
Race — White1128112610993353
Race — Black or African American636583211
Race — Asian655655176
Race — Other199209214622
08

Study locations

345 sites
  • University of Alabama at Birmingham (UAB), Arthritis Clinical Intervention Program
    Birmingham, Alabama 35294-7201, United States
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Clinical and Translational Research Center of Alabama, PC
    Tuscaloosa, Alabama 35406, United States
  • Southern Arizona VA Health Care System (SAVAHCS)
    Tucson, Arizona 85723, United States
  • University of Arizona Clinical and Translational Science Research Center
    Tucson, Arizona 85724, United States
  • CHI St. Vincent Medical Group Hot Springs
    Hot Springs, Arkansas 71913, United States
  • Arthritis And Rheumatism Associates LLC
    Jonesboro, Arkansas 72401, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • Med Investigations, Inc.
    Fair Oaks, California 95628, United States
  • Talbert Medical Group
    Huntington Beach, California 92646, United States
  • University of California, San Diego (UCSD)- Perlman Ambulatory Clinic
    La Jolla, California 92037, United States
  • Valerius Medical Group And Research Center Of Greater Long Beach, Inc.
    Long Beach, California 90806, United States
  • ProHealth Partners
    Long Beach, California 90808, United States
  • Keck Medicine of USC
    Los Angeles, California 90033, United States
  • California Medical Research Associates Inc
    Northridge, California 91324, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Medvin Clinical Research
    Placentia, California 92870, United States
  • Sierra Rheumatology, Inc.
    Roseville, California 95661, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Dr. Orrin M. Troum, Md And Medical Associates
    Santa Monica, California 90404, United States
  • Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
    Torrance, California 90502, United States
  • Harbor UCLA Medical Center
    Torrance, California 90509, United States
  • Robin K. Dore M.D., Inc.
    Tustin, California 92780, United States
  • Medvin Clinical Research
    Van Nuys, California 91405, United States
  • Ventura Clinical Trials
    Ventura, California 93003, United States
  • Desert Valley Medical Group
    Victorville, California 92395, United States
  • Medvin Clinical Research
    Whittier, California 90602, United States
  • Arthritis Associates and Osteoporosis Center of Colorado Springs
    Colorado Springs, Colorado 80920, United States
  • Howard University Hospital
    Washington, District of Columbia 20060, United States
  • RASF-Clinical Research Center, Inc
    Boca Raton, Florida 33486, United States
  • Bay Area Arthritis and Osteoporosis
    Brandon, Florida 33511, United States
  • Arthritis & Rheumatism Associates (Private Practice)
    Clearwater, Florida 33756, United States
  • Florida Clinical Research Group (Administrative Office)
    Clearwater, Florida 33759, United States
  • Dr.Robert W. Levin MDOffice of
    Clearwater, Florida 33765, United States
  • International Medical Research
    Daytona Beach, Florida 32117, United States
  • Centre for Rheumatology, Immunology and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • University of Florida - Rheumatology at ACC
    Jacksonville, Florida 32207, United States
  • University of Florida College of Medicine, Jacksonville - Rheumatology Research
    Jacksonville, Florida 32207, United States
  • San Marcus Research Clinic
    Miami Lakes, Florida 33014, United States
  • Doctors Research Institute
    Miami, Florida 33145, United States
  • Center for Arthritis and Rheumatic Diseases
    Miami, Florida 33173, United States
  • Ocala Rheumatology Research Center
    Ocala, Florida 34474, United States
  • Advanced Clinical Research of Orlando
    Ocoee, Florida 34761, United States
  • Arthritis & osteoporosis treatment center,PA
    Orange Park, Florida 32073, United States
  • Rheumatology Associates of Central Florida, PA
    Orlando, Florida 32806, United States
  • Omega Research Consultants, LLC
    Orlando, Florida 32810, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Arthritis Center, Inc.
    Palm Harbor, Florida 34684, United States
  • Arthritis Research of Florida, Inc.
    Palm Harbor, Florida 34684, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Advanced Urgent Care
    Port Orange, Florida 32127, United States
  • USF Health Morsani Center for Advanced Healthcare
    Tampa, Florida 33612, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Arthritis and Rheumatology of GA, P.C.
    Atlanta, Georgia 30342, United States
  • Medical Associates of North Georgia - Rheumatology
    Canton, Georgia 30115, United States
  • Office of Jefrey D. Lieberman, MD, PC
    Decatur, Georgia 30033, United States
  • Coeur D'Alene Arthritis Clinic
    Coeur d'Alene, Idaho 83814, United States
  • Quincy Medical Group
    Quincy, Illinois 62301, United States
  • Springfield Clinic
    Springfield, Illinois 62702, United States
  • Diagnostic Rheumatology and Research PC
    Indianapolis, Indiana 46227, United States
  • MidWest Clinical Research, LLC
    Overland Park, Kansas 66209, United States
  • Professional Research Network of Kansas, LLC
    Wichita, Kansas 67205-1138, United States
  • Arthritis and Diabetes Clinic, Inc.
    Monroe, Louisiana 71203, United States
  • Klein & Associates, M.D.,P.A.
    Cumberland, Maryland 21502, United States
  • Arthritis Treatment Center
    Frederick, Maryland 21702, United States
  • Klein & Associates, MD, PA
    Hagerstown, Maryland 21740, United States
  • The Center for Rheumatology and Bone Research, a division of Arthritis and Rheumatism Associates, PC
    Wheaton, Maryland 20902, United States
  • Phase III Clinical Research
    Fall River, Massachusetts 02720, United States
  • UMass Memorial Medical Center, Memorial Campus
    Worcester, Massachusetts 01605, United States
  • Bronson Healthcare Group
    Battle Creek, Michigan 49015, United States
  • Bronson Rheumatology Specialists
    Kalamazoo, Michigan 49007, United States
  • Jasper Clinic, Inc.
    Kalamazoo, Michigan 49007, United States
  • Western Michigan University Homer Stryker M.D. School of Medicine Center for Clinical Research
    Kalamazoo, Michigan 49008, United States
  • Borgess Medical Center
    Kalamazoo, Michigan 49048, United States
  • Borgess Research Institute
    Kalamazoo, Michigan 49048, United States
  • June DO,PC
    Lansing, Michigan 48910, United States
  • Shores Rheumatology P.C.
    Saint Clair Shores, Michigan 48081, United States
  • St. Paul Rheumatology, PA
    Eagan, Minnesota 55121, United States
  • Center for Diagnostic Imaging
    Mendota Heights, Minnesota 55118, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Kansas City Internal Medicine
    Kansas City, Missouri 64114, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65810, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Westroads Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • University of Nevada School of Medicine
    Las Vegas, Nevada 89102, United States
  • Steinberg Diagnostics
    Las Vegas, Nevada 89109, United States
  • EKSAKTI, LLC (dba: Eksakti Clinical Research)
    Las Vegas, Nevada 89128, United States
  • Arthritis Center Of Reno
    Reno, Nevada 89502, United States
  • Nashua Rheumatology
    Nashua, New Hampshire 03060, United States
  • Summit Medical Group
    Clifton, New Jersey 07012, United States
  • Weill Cornell Physicians at Brooklyn Heights
    Brooklyn, New York 11201, United States
  • Northwell Health Division of Rheumatology
    Great Neck, New York 11021, United States
  • NYU Langone Rheumatology Associates Long Island.
    Lake Success, New York 11042, United States
  • EmergeOrtho,P.A.
    Durham, North Carolina 27704, United States
  • Physicians East, PA
    Greenville, North Carolina 27834, United States
  • PMG Research of Hickory LLC
    Hickory, North Carolina 28601, United States
  • Frycare outpatient imaging Center
    Hickory, North Carolina 28602, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • PMG Research Inc., d/b/a PMG Research of Piedmont HealthCare
    Statesville, North Carolina 28625, United States

Showing the first 100 of 345 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD Open. 2022 Nov;8(2):e002571. doi: 10.1136/rmdopen-2022-002571. PubMed 36323490 ↗
  • Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023 Jan;82(1):119-129. doi: 10.1136/ard-2022-222259. Epub 2022 Sep 22. PubMed 36137735 ↗
  • Balanescu AR, Citera G, Pascual-Ramos V, Bhatt DL, Connell CA, Gold D, Chen AS, Sawyerr G, Shapiro AB, Pope JE, Schulze-Koops H. Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2022 Nov;81(11):1491-1503. doi: 10.1136/ard-2022-222405. Epub 2022 Aug 3. Erratum In: Ann Rheum Dis. 2023 Oct;82(10):e219. doi: 10.1136/ard-2022-222405corr1. PubMed 35922124 ↗
  • Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316-326. doi: 10.1056/NEJMoa2109927. PubMed 35081280 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Jul 2020, 76 months.

Results were first posted in Aug 2021, 1 year after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 76 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2014
First posted
Mar 20, 2014
StartActual
Mar 14, 2014
Primary completionActual
Jul 22, 2020
CompletionActual
Jul 22, 2020
Results first posted
Aug 17, 2021
Last update
Aug 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02092467
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 20, 2014
Start date
Mar 14, 2014
Primary completion
Jul 22, 2020
Completion
Jul 22, 2020
Results posted
Aug 17, 2021
Last update
Aug 17, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion